FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis

On June 9, 2026, the FDA approved a once-every-8-week (Q8W) maintenance dosing regimen for lebrikizumab-lbkz (EBGLYSS; Eli Lilly), expanding the approved dosing options for adults and adolescents 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis (AD) not adequately controlled by topical prescription therapies.¹ The updated label allows patients to receive as few as 6 maintenance injections per year, without a mandated concomitant topical, making lebrikizumab the only biologic in this class with an approved regimen at this frequency.¹

"Today's approval builds on EBGLYSS' established long-term durability, with a new option for one maintenance dose every 8 weeks," said Adrienne Brown, executive vice president and president of Lilly Immunology. "For people living with moderate-to-severe atopic dermatitis, that means a treatment they only need to take as few as 6 times a year—without prescription topicals from the start."

ADjoin Q8W extension: trial design and efficacy data for lebrikizumab maintenance dosing

The regulatory submission was grounded in longitudinal exposure-response modeling combined with clinical data from the Q8W extension of the phase 3 ADjoin long-term study (NCT04392154).¹ The extension enrolled adult and adolescent patients (ages 12–17, weighing ≥40 kg) who had completed 100 weeks in the core ADjoin program—itself incorporating patients from the ADvocate 1 and 2, ADore, and ADopt-VA trials.¹ Over a 32-week open-label period, participants received lebrikizumab 250 mg Q8W or every four weeks (Q4W), regardless of their prior treatment cadence or response status at enrollment into the extension.¹

No new safety signals emerged during the 32-week extension, and no patient discontinued treatment due to adverse events over this period.¹ The most frequently reported adverse reactions (≥1%) across the lebrikizumab development program are conjunctivitis, injection site reactions, and herpes zoster.¹

It is worth noting that the Q8W approval rests substantially on modeling data rather than a prospective, head-to-head randomized comparison of Q4W versus Q8W dosing initiated from the start of treatment. The extension enrolled patients who were already established on therapy after 100 weeks—a population that may not fully represent those initiating treatment in routine clinical practice.

Disease burden of atopic dermatitis in the United States

Atopic dermatitis is among the most prevalent chronic inflammatory skin conditions in the US. National Health Interview Survey data from 2024 estimated AD prevalence at 7.6% in adults (approximately 19.8 million individuals) and 12.7% in children.² The disease imposes a substantial comorbidity burden, including asthma, food allergy, anxiety, depression, and cardiovascular conditions, alongside marked impairments in sleep quality and health-related quality of life.³ For patients with moderate-to-severe disease specifically, the treatment experience is compounded by time-intensive topical regimens that must be maintained between biologic doses under many existing protocols.

Mechanism of action and prior regulatory history for lebrikizumab

Lebrikizumab is a monoclonal antibody that selectively targets IL-13, binding the cytokine at a site that overlaps with the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, thereby preventing receptor complex formation and downstream IL-13 signaling.¹ IL-13 is considered a central driver of the type 2 inflammatory pathway underlying AD pathophysiology.¹ Unlike dupilumab, which targets the shared IL-4Rα receptor subunit to block both IL-4 and IL-13 signaling, lebrikizumab acts directly on the IL-13 cytokine itself.

Lebrikizumab was initially approved in the European Union in 2023 and received US, Japanese, and Canadian approval in 2024.¹ The standard induction regimen in the US is 500 mg (two 250 mg injections) at weeks 0 and 2, followed by 250 mg every 2 weeks through week 16 or until adequate clinical response is achieved; the approved maintenance options are now 250 mg Q4W or 250 mg Q8W.¹

Dosing flexibility and the unmet need in moderate-to-severe atopic dermatitis management

The addition of a Q8W maintenance option addresses a documented tension in chronic disease management: reduced injection frequency may support long-term adherence, which in turn is a prerequisite for sustained disease control in a condition measured in years, not weeks. Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University and author of the ADjoin study, noted that the dosing option without mandatory topicals allows individualization: "It's about meeting patients where they are in their lives."

Whether the Q8W regimen will perform equivalently to Q4W in patients who are newly initiating therapy, rather than those who have already demonstrated response and tolerability over nearly 2 years, remains an open question. Lilly has disclosed that a trial investigating 500 mg Q12W maintenance dosing is underway, suggesting the company sees room for further extension of dosing intervals.

References

1. Eli Lilly. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. Eli Lilly. June 9, 2026. Accessed June 10, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglyssr-lebrikizumab-lbkz-one-maintenance

2. Silverberg JI, Barbarot S, Gadkari A, et al. Prevalence of atopic dermatitis in the United States from 2021 to 2024: data from the National Health Interview Survey. J Am Acad Dermatol. 2026;94(2):633–635.

3. Silverberg JI, Anderson P, Cappelleri JC, et al. Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States. Arch Dermatol Res. 2025. doi:10.1007/s00403-025-03910-y

4. Silverberg J, et al. Lebrikizumab every 8 weeks as maintenance dose provides long-lasting response in patients with moderate-to-severe atopic dermatitis. Presented at: Fall Clinical Dermatology Conference; October 2025.